Market Access

Evidence-based reimbursement decisions and the role of formal cost-effectiveness assessments

Understand the advantages and the impact of your products in the context of the national health systems, from a pricing/health outcomes perspective. Some of the evidence-based reimbursement decision are based on a few key items which will need to be defined for your product such as:

1. Efficient and “cost-effective” utilization of scarce (health care) resources as an important policy objective in the presence of limited budgets and opportunity costs
2. Effective delivery against a multitude of implicitly or explicitly articulated objectives for which decision makers are politically accountable i.e. not simply the maximization of QALYs
3. Trade-offs between patient groups and their different needs in the presence of a multitude of potentially conflicting health care policy objectives
4. Formal health economic evaluation methodology can play a valuable role when selecting the most [technically/productively] efficient technology: to achieve a defined clinical goal with a minimum amount of resources or to maximize a specific clinical outcome from a defined budget as long as the very same patient population is affected.